| __timestamp | Amgen Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 302156000 |
| Thursday, January 1, 2015 | 4846000000 | 402271000 |
| Friday, January 1, 2016 | 5062000000 | 476593000 |
| Sunday, January 1, 2017 | 4870000000 | 554336000 |
| Monday, January 1, 2018 | 5332000000 | 604353000 |
| Tuesday, January 1, 2019 | 5150000000 | 680924000 |
| Wednesday, January 1, 2020 | 5730000000 | 737669000 |
| Friday, January 1, 2021 | 5368000000 | 759375000 |
| Saturday, January 1, 2022 | 5414000000 | 854009000 |
| Sunday, January 1, 2023 | 6179000000 | 937300000 |
| Monday, January 1, 2024 | 7096000000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, operational efficiency is key. Over the past decade, Amgen Inc. and BioMarin Pharmaceutical Inc. have showcased distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. Amgen, a giant in the industry, has consistently maintained higher SG&A expenses, peaking at approximately $6.2 billion in 2023, reflecting its expansive operations and market reach. In contrast, BioMarin, a smaller yet innovative player, has seen its SG&A expenses grow by over 200% from 2014 to 2023, reaching nearly $937 million. This growth underscores BioMarin's aggressive expansion and investment in market penetration. The data reveals a fascinating narrative of scale versus growth, with Amgen's expenses being roughly six times that of BioMarin's in 2023. As these companies continue to evolve, their SG&A strategies will remain pivotal in shaping their competitive edge.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Amgen Inc. vs Pharming Group N.V. Trends and Insights
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amgen Inc. and Perrigo Company plc
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation